DRKS00006005
Completed
N/A
A pilot study to investigate safety and effectiveness of Collagen Matrix 10808 to increase soft tissue thickness simultaneous to GBR and implant placement
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- K08.1
- Sponsor
- Geistlich Pharma AG
- Enrollment
- 10
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients will be included in the study if they present all of the following conditions:
- •Signed informed consent
- •Age 18 years or older
- •Absence of significant medical conditions
- •Patients with healthy or effectually treated periodontal conditions
- •Full\-Mouth Plaque score less than 25% (O’Leary et al. 1972\)
- •Candidate for single tooth replacement in the anterior maxilla
- •Implant sites with the need for contour augmentation using GBR (Chen \& Buser 2009\)
- •Implant sites which allow the concept of early implant placement after tooth extraction
Exclusion Criteria
- •Patients will not be included in the study if they present one of the following conditions:
- •General contraindications for dental and/or surgical treatments
- •Immunosuppressant, corticosteroid or bisphosphonate therapy
- •Inflammatory or autoimmune disease of oral cavity
- •History of malignancy, radiotherapy or chemotherapy for malignancy within the past five years.
- •Uncontrolled diabetes
- •Pregnant or lactating women
- •Women of child bearing age, not using a standard accepted method of birth control
- •Allergy to collagen
- •Participation in an investigational device, drug or biologic study within the last 24 weeks prior to the study start
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, Not Recruiting
N/A
A pilot study to investigate the safety and efficacy of a combined treatment with Gemcitabine and Sulfasalazine in pancreatic ductal adenocarcinomaPancreatic ductal adenocarcinoma, non resectableMedDRA version: 9.1Level: LLTClassification code 10033600Term: Pancreatic adenocarcinoma non-resectableEUCTR2006-005104-14-DEniversitätsklinikum Schleswig-Holstein20
Not Yet Recruiting
Phase 2
Effectiveness of Low carb products in mitigating blood sugar spikes in patients with Type 2 Diabetes Mellitus.CTRI/2023/05/053173Bajo Foods Pvt Ltd
Active, Not Recruiting
N/A
A pilot study to evaluate the efficacy and safety of different bindarit dosages in preventing stent restenosis - NDPATIENTS WITH BARE METAL STENT IMPLANTMedDRA version: 9.1Level: HLGTClassification code 10003216Term: Arteriosclerosis, stenosis, vascular insufficiency and necrosisEUCTR2008-004921-40-ITANGELINI
Not Yet Recruiting
N/A
Effect of low carbohydrate food products on diabeticsCTRI/2022/10/046931Bajo Foods Pvt Ltd
Completed
N/A
Pilot study for a new oral immunotherapy for peanut allergyPeanut allergyInflammatory and Immune System - AllergiesACTRN12614000919617Dr Billy Tao15